Skip to main content

Advertisement

Table 1 Baseline imaging characteristics

From: Resolution of synovitis and arrest of catabolic and anabolic bone changes in patients with psoriatic arthritis by IL-17A blockade with secukinumab: results from the prospective PSARTROS study

Magnetic resonance imaging
 Synovitis % 90%
  PSAMRIS Synovitis (median, IQR) 2.5 (1.25, 6)
 Osteitis % 20%
  PSAMRIS Osteitis (median, IQR) 0 (0, 0)†
  PSAMRIS Osteitis (mean ± SD) 1 ± 2.8
 Erosion % 60%
  PSAMRIS Erosion (median, IQR) 1 (0, 2.75)
 Proliferation % 30%
  PSAMRIS Proliferation (median, IQR) 0 (0, 1)†
  PSAMRIS Proliferation (mean ± SD)† 1.1 ± 2.4
 Periarticular % 25%
  PSAMRIS Periarticular (median, IQR) 0 (0, 1.5)†
  PSAMRIS Periarticular (mean ± SD)† 0.8 ± 1.6
 Tenosynovitis % 35%
  PSAMRIS Tenosynovitis (median, IQR) 0 (0, 1.75)†
  PSAMRIS Tenosynovitis (mean ± SD)† 1.6 ± 2.9
 Total PSAMRIS (median, IQR) 5.5 (3, 19.5)
PDUS
 Synovitis % 70%
  OMERACT Hypertrophy (median, IQR) 5.5. (2.25, 10.75)
  OMERACT Effusion (median, IQR) 4.5 (1, 8.5)
  OMERACT Power Doppler (median, IQR) 2 (1.25, 5.75)
  OMERACT Global (median, IQR) 5 (3, 11)
HR-pQCT
 Erosions (%) 73.7%
 Enthesiophytes (%) 89.5%
  1. HR-pQCT high-resolution peripheral quantitative computed tomography, IQR interquartile range, OMERACT outcome measures in rheumatoid arthritis clinical trials, PDUS power Doppler ultrasound, PSAMRIS psoriatic arthritis magnetic resonance imaging scoring system. †Additionally reported as mean and standard deviation (mean ± standard deviation) because median was equal to zero. Data are based on all 20 psoriatic arthritis patients recruited into the study